SRPT - Sarepta Therapeutics Inc Stock Price, Fair Value and News

$35.38-0.36 (-1.01%)

Delayed as of 15 May 2025, 02:24 pm ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SRPT Price Action

Last 7 days

-2.7%

Last 30 days

-34.6%

Last 90 days

-67.3%

Trailing 12 Months

-73.1%

SRPT RSI Chart

SRPT Valuation

Market Cap

3.5B

Price/Earnings (Trailing)

-14.14

Price/Sales (Trailing)

1.57

EV/EBITDA

-29.91

Price/Free Cashflow

-5.05

SRPT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SRPT Fundamentals

SRPT Revenue

Revenue (TTM)

2.2B

Rev. Growth (Yr)

80.15%

Rev. Growth (Qtr)

13.13%

SRPT Earnings

Earnings (TTM)

-248.4M

Earnings Growth (Yr)

-1.3K%

Earnings Growth (Qtr)

-381.36%

SRPT Profitability

EBT Margin

-7.35%

Return on Equity

-21.74%

Return on Assets

-7.17%

Free Cashflow Yield

-19.8%

SRPT Investor Care

Shares Dilution (1Y)

3.97%

Diluted EPS (TTM)

-2.63

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	2.2B	0	0	0
2024	1.4B	1.5B	1.6B	1.9B
2023	975.7M	1.0B	1.1B	1.2B
2022	765.8M	835.2M	876.0M	933.0M
2021	573.4M	600.1M	645.6M	701.9M
2020	407.5M	450.2M	495.1M	540.1M
2019	323.4M	344.6M	365.1M	380.8M
2018	202.8M	241.4M	273.9M	301.0M
2017	37.9M	70.3M	102.7M	154.6M
2016	5.0M	5.2M	5.3M	5.4M
2015	0	0	0	4.9M
2014	15.8M	15.5M	12.4M	9.8M
2013	30.6M	22.3M	18.9M	14.2M
2012	43.9M	43.5M	43.6M	37.3M
2011	42.5M	50.1M	48.9M	47.0M
2010	0	21.5M	25.5M	29.4M
2009	0	0	0	17.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Douglas S. Ingram Esq.
WEBSITE	sarepta.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	1162

Sarepta Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Sarepta Therapeutics Inc? What does SRPT stand for in stocks?

SRPT is the stock ticker symbol of Sarepta Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sarepta Therapeutics Inc (SRPT)?

As of Wed May 14 2025, market cap of Sarepta Therapeutics Inc is 3.51 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SRPT stock?

You can check SRPT's fair value in chart for subscribers.

Is Sarepta Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SRPT is over valued or under valued. Whether Sarepta Therapeutics Inc is cheap or expensive depends on the assumptions which impact Sarepta Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SRPT.

What is Sarepta Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 14 2025, SRPT's PE ratio (Price to Earnings) is -14.14 and Price to Sales (PS) ratio is 1.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SRPT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Sarepta Therapeutics Inc's stock?

In the past 10 years, Sarepta Therapeutics Inc has provided 0.089 (multiply by 100 for percentage) rate of return.